<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04512287</url>
  </required_header>
  <id_info>
    <org_study_id>20200779</org_study_id>
    <nct_id>NCT04512287</nct_id>
  </id_info>
  <brief_title>PRP for Treatment of Peyronie's Disease</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo Controlled, Crossover Trial on Safety and Efficacy of Autologous Platelet-Rich Plasma for Treatment of Peyronie's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn about the effects of Platelet-Rich Plasma (PRP)&#xD;
      injection in men with Peyronie's Disease (PyD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects in each group who attain degree change in penile curvature.</measure>
    <time_frame>12 months</time_frame>
    <description>Treatment efficacy of PRP will be assessed via the percentage of participants achieving degree change in penile curvature from baseline. Degree of curvature will be measured using a goniometer with the aid of injection of vasoactive substance into the penis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects achieving any decrease in PDQ sub-domain scores (Psychological and Physical Symptoms, Symptom Bother).</measure>
    <time_frame>12 months</time_frame>
    <description>Treatment efficacy will be assessed via the percentage of participants achieving any decrease in Peyronie's disease Questionnaire (PDQ) sub-domain scoring from baseline. The sub-domains that will be assessed in primary outcome is Psychological and Physical Symptoms and Symptom Bother. PDQ is a validated 15-item questionnaire that assess Psychological and Physical Symptoms, Symptom Bother, and Penile Pain subdomains. The Psychological and Physical Symptoms subdomain is measured from 0 to 24 (most severe symptoms). Symptom Bother subdomain is measured from 0 to 30 (most severe pain).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events in all patients</measure>
    <time_frame>Baseline, 6 months (post-intervention)</time_frame>
    <description>Safety will be evaluated via the incidence of adverse events as assessed by treating physician</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Peyronie Disease</condition>
  <condition>Sexual Dysfunction, Physiological</condition>
  <condition>Sexual Dysfunction Male</condition>
  <condition>Genital Diseases, Male</condition>
  <arm_group>
    <arm_group_label>Experimental: Autologous PRP followed by Placebo Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive the autologous intervention first, followed by the placebo intervention 6 months later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Placebo followed by Autologous PRP Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive the placebo intervention first, followed by the Autologous PRP intervention 6 months later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Autologous Platelet Rich Plasma</intervention_name>
    <description>2 sessions of Autologous PRP will be administered 15 days apart. Each injection will be 0.5 mL of PRP injected into the Peyronie's disease penile plaque.</description>
    <arm_group_label>Experimental: Autologous PRP followed by Placebo Group</arm_group_label>
    <arm_group_label>Experimental: Placebo followed by Autologous PRP Group</arm_group_label>
    <other_name>PRP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline Solution</intervention_name>
    <description>2 sessions of saline injection will be administered 15 days apart. Each injection will be 0.5 mL of normal saline injected into the Peyronie's disease penile plaque.</description>
    <arm_group_label>Experimental: Autologous PRP followed by Placebo Group</arm_group_label>
    <arm_group_label>Experimental: Placebo followed by Autologous PRP Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be Male&#xD;
&#xD;
          2. Be 18 to 75 years of age (inclusive).&#xD;
&#xD;
          3. Be able to provide written informed consent&#xD;
&#xD;
          4. Have a diagnosis of PD with evidence of active or stable disease as determined by the&#xD;
             investigator&#xD;
&#xD;
          5. Penile curvature deformity of &gt;30° to &lt;120°&#xD;
&#xD;
          6. Agree to comply with all study related tests/procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous penile surgery of any kind (except circumcision and condyloma removal), such&#xD;
             as penile lengthening, penile cancer surgery, penile plication, grafting.&#xD;
&#xD;
          2. Previous intralesional injection therapy (such as Xiaflex) for PD.&#xD;
&#xD;
          3. Previous history of priapism or penile fracture&#xD;
&#xD;
          4. PD characterized by a ventral plaque&#xD;
&#xD;
          5. Severe erectile dysfunction as characterized with an International Index of Erectile&#xD;
             Function (IIEF) score ≤ 16&#xD;
&#xD;
          6. Actively on anticoagulation during time frame of injections (aspirin 81 mg will be&#xD;
             eligible for therapy)&#xD;
&#xD;
          7. Hour-glass deformity&#xD;
&#xD;
          8. Unwilling to participate&#xD;
&#xD;
          9. Medically unfit for sexual intercourse as deemed by the principal investigator&#xD;
&#xD;
         10. Patients scheduled to undergo an elective medical procedure during the investigation&#xD;
             timeframe that will interfere with autologous PRP injection therapy.&#xD;
&#xD;
         11. Have a serious comorbid illness/condition/behavior that, in the opinion of the&#xD;
             investigator, may compromise the safety or compliance of the subject or preclude&#xD;
             successful completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ranjith Ramasamy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kevin Chu, MD</last_name>
    <phone>305-243-4562</phone>
    <email>kevin.chu@jhsmiami.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ranjith Ramasamy, MD</last_name>
    <phone>305-243-4562</phone>
    <email>ramasamy@miami.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Chu, MD</last_name>
      <phone>305-243-4562</phone>
      <email>kevin.chu@jhsmiami.org</email>
    </contact>
    <investigator>
      <last_name>Ranjith Ramasamy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Ranjith Ramasamy, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>PD</keyword>
  <keyword>PyD</keyword>
  <keyword>PRP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Penile Induration</mesh_term>
    <mesh_term>Sexual Dysfunction, Physiological</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

